Gamida Cell (GMDAQ) 10-K 24 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	GAMIDA CELL LTD.
Trading Symbol	GMDA
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		60,002,190
Entity Public Float			$ 379,900,000
Amendment Flag	false
Entity Central Index Key	0001600847
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38716
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	116 Huntington Avenue
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	(713)
Local Phone Number	400-6400
Title of 12(b) Security	Ordinary Shares, NIS 0.01 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	1281
Auditor Name	KOST FORER GABBAY & KASIERER
Auditor Location	Tel-Aviv, Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 55,892	$ 127,170
Marketable securities	40,034
Prepaid expenses and other current assets	2,688	3,087
Total current assets	98,614	130,257
NON-CURRENT ASSETS:
Restricted deposits	3,961
Property, plant and equipment, net	35,180	18,238
Operating lease right-of-use assets	7,236	6,841
Severance pay fund	2,148	2,191
Other long-term assets	1,647	786
Total non-current assets	50,172	28,056
Total assets	148,786	158,313
CURRENT LIABILITIES:
Trade payables	8,272	6,331
Employees and payroll accruals	4,957	4,705
Operating lease liabilities	2,699	2,475
Accrued interest of convertible senior notes	1,640
Accrued expenses and current liabilities	7,865	7,988
Total current liabilities	25,433	21,499
NON-CURRENT LIABILITIES:
Convertible senior notes, net	71,417
Accrued severance pay	2,396	2,426
Long-term operating lease liabilities	5,603	5,517
Total non-current liabilities	79,416	7,943
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Ordinary shares of NIS 0.01 par value - Authorized: 150,000,000 and 100,000,000 shares at December 31, 2021 and 2020, respectively; Issued and outstanding: 59,970,389 and 59,000,153 shares at December 31, 2021 and 2020, respectively	169	166
Additional paid-in capital	381,225	376,369
Accumulated deficit	(337,457)	(247,664)
Total shareholders’ equity	43,937	128,871
Total liabilities and shareholders’ equity	$ 148,786	$ 158,313

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - ₪ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Ordinary shares par value (in New Shekels per share)	₪ 0.01	₪ 0.01
Ordinary shares authorized	150,000,000	100,000,000
Ordinary shares Issued	59,970,389	59,000,153
Ordinary shares outstanding	59,970,389	59,000,153

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Research and development expenses, net	$ 50,177	$ 38,873
Commercial expenses	20,013	8,894
General and administrative expenses	16,977	13,158
Total operating loss	87,167	60,925
Financial expenses, net	2,626	648
Loss	$ 89,793	$ 61,573
Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)	$ 1.52	$ 1.41
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)	59,246,803	43,725,584

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Equity - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2019	$ 92	$ 239,577	$ (186,091)	$ 53,578
Balance (in Shares) at Dec. 31, 2019	33,670,926
Loss			(61,573)	(61,573)
Issuance of Ordinary shares, net of issuance expenses of $10,902	$ 72	132,776		132,848
Issuance of Ordinary shares, net of issuance expenses of $10,902 (in Shares)	24,677,084
Exercise of options	$ 2	648		650
Exercise of options (in Shares)	652,143
Share-based compensation		3,368		3,368
Balance at Dec. 31, 2020	$ 166	376,369	(247,664)	128,871
Balance (in Shares) at Dec. 31, 2020	59,000,153
Loss			(89,793)	(89,793)
Grant of restricted shares	$ 2	(2)
Grant of restricted shares (in Shares)	531,477
Exercise of options	$ 1	625		626
Exercise of options (in Shares)	438,759
Share-based compensation		4,233		4,233
Balance at Dec. 31, 2021	$ 169	$ 381,225	$ (337,457)	$ 43,937
Balance (in Shares) at Dec. 31, 2021	59,970,389

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders’ Equity (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance expenses	$ 10,902

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Loss	$ (89,793)	$ (61,573)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation of property, plant and equipment	431	357
Financing expense, net	359	166
Share-based compensation	4,233	3,368
Amortization of debt discount and issuance costs	638
Operating lease right-of-use assets	2,109	1,891
Operating lease liabilities	(2,193)	(1,318)
Accrued severance pay, net	12
Decrease (increase) in prepaid expenses and other assets	1,008	(1,630)
Increase in trade payables	1,941	5,066
Increase (decrease) in accrued expenses and current liabilities	(505)	3,454
Net cash used in operating activities	(81,760)	(50,219)
Cash flows from investing activities:
Purchase of property, plant and equipment	(15,054)	(11,804)
Purchase of marketable securities	(102,179)
Proceeds from maturity of marketable securities	61,534	13,551
Investment in restricted deposits	(5,222)	(158)
Net cash provided by (used in) investing activities	(60,921)	1,589
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net		133,312
Proceeds from exercise of options	626	650
Proceeds from issuance of convertible senior notes, net	70,777
Net cash provided by financing activities	71,403	133,962
Increase (decrease) in cash and cash equivalents	(71,278)	85,332
Cash and cash equivalents at beginning of year	127,170	41,838
Cash and cash equivalents at end of year	55,892	127,170
Significant non-cash transactions:
Lease liabilities arising from new right-of-use asset	2,503	3,373
Issuance expenses on credit		468
Purchase of property, plant and equipment on credit	634	415
Supplemental disclosures of cash flow information:
Cash paid for interest	$ 2,572	$ 34

General

General	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
GENERAL	NOTE 1: GENERAL a. Gamida Cell Ltd. (the “Company”), founded in 1998, is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases. The Company develops novel curative treatments using stem cells and Natural Killer (NK) cells. b. The Company has created a novel NAM cell expansion technology platform that is designed to enhance the number and functionality of allogenic donor cells. This proprietary therapeutic platform may enable the development of therapies with the potential to improve treatment outcomes beyond what is possible with current donor-derived therapies. The lead product candidate, omidubicel, is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant (BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase 3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived from bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients, but there is a significant unmet need for patients who cannot find a fully matched donor. In October 2020, the Company reported that omidubicel met all three of its secondary endpoints. In October 2021, the complete results from our pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published in the peer-reviewed medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints demonstrated statistical significance in an intent-to-treat analysis. Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has received orphan drug designation in the U.S. and in Europe. In addition to omidubicel, the Company is developing GDA-201, an investigational NK cell-based cancer immunotherapy to be used in combination with standard-of-care therapeutic antibodies. NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching, potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. GDA-201 is currently in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). In December 2020, the Company reported updated and expanded results from the Phase 1 clinical study at the Annual Meeting of the American Society of Hematology, or ASH. The data from the first 35 patients demonstrated that GDA-201 was clinically active and generally well tolerated. Among the 19 patients with NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74 percent and a complete response rate of 68 percent. At the December 2021 Annual Meeting of ASH, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers associated with survival. The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95% CI, 51%–91%) and a safety profile similar to that reported previously. c. The Company is devoting substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of December 31, 2021 was $337,457 and negative cash flows from operating activities during the year ended December 31, 2021 was $81,760. The Company is planning to finance its operations from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However, there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in amounts required. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least twelve months from the issuance of the consolidated financial statements. d. The Company has a wholly-owned U.S. subsidiary, Gamida Cell Inc. (the “Subsidiary”), which was incorporated in 2000, under the laws of the State of Delaware. The Company has one operating segment and reporting unit.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2: SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation of the financial statements: The Company’s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) as set forth in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (ASC). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB), as permitted in the United States based on the Company’s qualification as a “foreign private issuer” under the rules and regulations of the U.S Securities and Exchange Commission (the “SEC”). In connection with the loss of the Company’s status as a foreign private issuer effective on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP. b. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation. d. Consolidated financial statements in U.S dollars: The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiary operates and conducts their transactions. Most of the Company’s costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC No. 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the statements of operations as financing income or expenses as appropriate. e. Cash and cash equivalents: Cash equivalents are short-term highly liquid deposits that are readily convertible to cash with original maturities of three months or less, at the date acquired. f. Investments in marketable securities: The Company’s investment in marketable securities consist primarily of trading bonds with a quoted market price that are classified as trading securities pursuant to ASC 320 “Investments — Debt Securities.” Marketable securities are stated at fair value as determined by the closing price of each security at balance sheet date. Unrealized gains and losses on these securities are included in financing income in the consolidated statements of operations. g. Restricted short-term and long-term deposits: Restricted short-term deposits are deposits with maturities of up to one year and are used as security for the Company’s credit cards. Restricted short-term deposits amounted to $500 and $152 as of December 31, 2021 and 2020, respectively, and are included in prepaid expenses and other current assets in the consolidated balance sheets. Restricted long-term deposits are deposits with maturities of more than one year and are used as guarantee for the Israeli Investment Center grant expected in 2022 and as security for the rental of premises and for the Company’s credit cards. Restricted long-term deposits amounted to $3,961 as of December 31, 2021, as presented in the consolidated balance sheet. h. Property, plant and equipment: Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants, excluding day-to-day servicing expenses. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Machinery 10 - 15 Office, furniture and equipment 6 - 33 Leasehold improvements (*) Project in process- manufacturing plant (**) (*) Over the shorter of the term of the lease or its useful life. (**) As of December 31, 2021, the manufacturing plant is under validation process and therefore is not yet ready for production. Depreciation of the manufacturing plant will commence upon completion of the validation process. i. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets through an impairment charge, to their estimated fair values. During the years ended December 31, 2021 and 2020, no impairment indicators have been identified. j. Research and development expenses: Research and development expenses net of grants are recognized in the consolidated statements of operations when incurred. Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, and executing pre-clinical and clinical studies. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as incurred. Royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by the IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognized the amounts of grants received in research and development as a reduction from research and development expenses in the amount of $2,189 and $1,204 for the years ended December 31, 2021 and 2020, respectively. k. Convertible senior notes: The Company accounts for its convertible senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options”. The Company early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40. The Company’s convertible senior notes are included in the calculation of diluted earnings per share (the “EPS”) if the assumed conversion into ordinary shares is dilutive, using the “if-converted” method. This involves adding back the periodic non-cash interest expense net of taxes associated with the convertible senior notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the denominator for the purposes of calculating diluted EPS. Since the effect of the convertible senior notes on the diluted EPS was antidilutive, the Company did not include them in the calculation of the diluted EPS. l. Share-based compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation - Stock Compensation”, which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis when the only condition to vesting is continued service. The Company has selected the binominal option-pricing model as the most appropriate fair value method for its option awards. The fair value of restricted shares is based on the closing market value of the underlying shares at the date of grant. The Company recognizes forfeitures of equity-based awards as they occur. m. Employee benefit liabilities: The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits are benefits that are expected to be settled entirely before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. 2. Severance pay The majority of the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (the “ Severance Pay Law Severance Pay Law For the Company’s employees in Israel who are not subject to Section 14 of the Severance Pay Law, the Company has a liability for severance pay pursuant to the Severance Pay Law based on the most recent salary of these employees multiplied by the number of years of employment as of the balance sheet date. The Company’s liability for these employees is fully provided for by monthly deposits with severance pay funds, insurance policies and accruals. The deposited funds include profits accumulated up to the balance sheet date. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The severance pay fund amounted to $2,148 and $2,191 as of December 31, 2021 and 2020, respectively. Accrued severance pay is $2,396 and $2,426 as of December 31, 2021 and 2020, respectively. n. Fair value of financial instruments: The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data are available. The carrying amounts of cash and cash equivalents, marketable securities, other receivables, short-term deposits, prepaid expenses and other current assets, trade payables, accrued expenses and other payables approximate their fair value due to the short-term maturity of such instruments. o. Leases: The Company accounts for leases according to ASC 842, “Leases”. The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize right-of-use (“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. An ROU asset represents the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease agreement. An ROU asset is measured based on the discounted present value of the remaining lease payments, plus any initial direct costs incurred and prepaid lease payments, excluding lease incentives. The lease liability is measured at lease commencement date based on the discounted present value of the remaining lease payments. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (“IBR”) based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. Payments under the Company’s lease arrangements are primarily fixed however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease right-of-use assets and liabilities. Variable lease payments are primarily comprised of payments affected by common area maintenance and utility charges. p. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”, which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. ASC 740 offers a two-step approach for recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740. q. Basic and diluted net loss per share: The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis. These participating securities do not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities. The Company’s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive ordinary shares are anti-dilutive. r. Recently issued accounting standards: In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the financial statements.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 3: MARKETABLE SECURITIES The following table details the fair value of trading marketable securities as of December 31, 2021: As of Fair value Corporate debentures $ 19,605 Government debentures 20,429 Total $ 40,034

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 4: PROPERTY, PLANT AND EQUIPMENT, NET The composition of property, plant and equipment is as follows: Year ended 2021 2020 Cost: Machinery $ 4,345 $ 3,545 Leasehold improvements 1,447 1,542 Office, furniture and equipment 800 627 Production plant in process 32,644 16,149 39,236 21,863 Less - accumulated depreciation (4,056 ) (3,625 ) Depreciated cost $ 35,180 $ 18,238 Depreciation expense amounted to $431 and $357 for the years ended December 31, 2021 and 2020, respectively.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
LEASES	NOTE 5: LEASES The Company entered into operating leases primarily for its in-process production plant, and its laboratories and offices. The leases have remaining lease terms of up to six years, The Company does not assume renewals in its determination of the lease term unless the renewals are considered as reasonably certain at lease commencement. The components of operating lease costs were as follows: Year ended December 31, 2021 2020 Operating lease costs $ 2,391 $ 2,140 Short-term lease costs 103 43 Total lease costs $ 2,494 $ 2,183 Supplemental balance sheet information related to operating leases is as follows: Year ended December 31, 2021 2020 Weighted average remaining lease term (in years) 4.31 5.17 Weighted average discount rate 2.54 % 2.45 % Maturities of lease liabilities were as follows : As of 2022 $ 2,771 2023 1,801 2024 1,808 2025 1,316 2026 790 Thereafter 613 Total undiscounted lease payments 9,099 Less: Imputed interest (797 ) Present value of lease liabilities $ 8,302

Convertible Senior Notes, Net

Convertible Senior Notes, Net	12 Months Ended
	Dec. 31, 2021
Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]
CONVERTIBLE SENIOR NOTES, NET	NOTE 6: CONVERTIBLE SENIOR NOTES, NET On February 16, 2021, the Subsidiary issued convertible senior notes (the “Convertible Notes”) due in 2026, in the aggregate principal amount of $75 million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February 16, 2021 (the “Indenture”). The Convertible Notes bear interest payable semiannually in arrears, at a rate of 5.875% per year. The Convertible Notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to the provisions of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $1,000 or an integral multiple thereof, into the Company’s ordinary shares at an initial conversion rate of 56.3063 shares per $1,000 principal amount of Convertible Notes (equivalent to an exchange price of $17.76 per share). The conversion rate is subject to adjustment in specified events. Upon the occurrence of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash all or a portion of their Convertible Notes, in multiples of $1,000 principal amount, at a repurchase price equal to 100% of the principal amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of such repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the Convertible Notes may be increased. Subject to the provisions of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to be redeemed, if the last reported closing price of the Company’s ordinary shares has been at least 130% of the exchange price then in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes. The Convertible Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40. As of 2021 Liability component: Principal amount $ 75,000 Issuance costs (4,223 ) Net issuance costs $ 70,777 Amortized issuance costs 640 Net carrying amount $ 71,417 The total issuance costs of the Convertible Notes amounted to $4,223 and are amortized to interest expenses at an annual effective interest rate of 7.37%, over the term of the Convertible Notes.

Accrued Expenses and Other Paya

Accrued Expenses and Other Payables	12 Months Ended
	Dec. 31, 2021
Disclosure Supplement [Abstract]
ACCRUED EXPENSES AND OTHER PAYABLES	NOTE 7: ACCRUED EXPENSES AND OTHER PAYABLES Year ended 2021 2020 Subcontractors $ 517 $ 609 Clinical activities 5,445 4,841 Professional services 740 1,943 Production plant in process 983 415 Other 180 180 $ 7,865 $ 7,988

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 8: FAIR VALUE MEASUREMENTS The following tables present the fair value of money market funds and marketable securities for the years ended December 31, 2021 and 2020: December 31, 2021 2020 Level 1 Level 2 Total Level 1 Level 2 Total Cash equivalents: Money market funds $ 51,021 $ - $ 51,021 $ 123 $ - $ 123 Marketable securities: Corporate debentures - 19,605 19,605 - - - Government debentures - 20,429 20,429 - - - Total assets measured at fair value $ 51,021 $ 40,034 $ 91,055 $ 123 $ - $ 123

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 9: CONTINGENT LIABILITIES AND COMMITMENTS a. Legal proceedings: From time to time the Company or its subsidiaries may be involved in legal proceedings and/or litigation arising in the ordinary course of business. While the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material effect on its consolidated financial position, results of operations, or cash flows. b. Bank guarantees: As of December 31, 2021, the Company obtained bank guarantees in the amount of $3,334, primarily in connection with an Investment Center grant of up to $3,171 expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant terms. NOTE 9: CONTINGENT LIABILITIES AND COMMITMENTS (Cont.) c. Governments grants The Company has received grants from the IIA to finance its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $37.3 million through December 31, 2021, of which $34.7 million is royalty-bearing grants and $2.6 million is non-royalty-bearing grants. In return, the Company is committed to pay IIA royalties at a rate of 3-3.5% of future sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2021, no royalties have been paid or accrued. The Company’s contingent royalty liability to the IIA at December 31, 2021, including grants received by the Company and the associated LIBOR interest on all such grants totaled to $44.7 million.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	NOTE 10: SHAREHOLDERS’ EQUITY a. Ordinary shares: Subject to the Company’s amended and restated Articles of Association, the holders of the Company’s ordinary shares have the right to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to share in dividends and other distributions upon liquidation. In May 2020, the Company closed a second follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of a total of 15,333,334 ordinary shares at a public offering price of $4.50 per share, before underwriting discounts and inclusive of the underwriters’ exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $63,860 from the offering (net of issuance costs and underwriting discounts of $5,140). In December 2020, the Company closed a third follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of 9,343,750 ordinary shares at a public offering price of $8.00 per share, before underwriting discounts and inclusive of the underwriters’ exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $68,988 from the offering (net of issuance costs and underwriting discounts of $5,762). b. Warrants to investors: As part of its 2017 investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022. As of December 31, 2021, 1,010,466 of the warrants have been exercised into the Company’s ordinary shares.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 11: SHARE-BASED COMPENSATION a. Option plans: On November 23, 2014, the Company’s Board of Directors approved, subject to the approval of the shareholders, creation of the Company’s ordinary C share class, with nominal value NIS 0.01 per share and classification of 1,500,000 ordinary shares for such class of shares, whereby 1,152,044 of such shares were allocated to the Company’s employees under the amended 2014 Israel Share Option Plan (the “2014 Plan”). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the shares into which the options are exercised. The options vest primarily over three years. There are no cash settlement alternatives. On December 29, 2014, the Company’s shareholders ratified and approved the aforesaid actions. On January 23, 2017, the Company’s Board of Directors approved the Company’s 2017 Share Incentive Plan (the “2017 Plan” and together with the 2014 Plan, the “Option Plans”), and the subsequent grant of options to the Company’s employees, officers and directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each. On February 28, 2017, the Company’s shareholders approved the 2017 Plan. The 2017 Plan provides for the grant of awards, including options, restricted shares and restricted share units to the Company’s directors, employees, officers, consultants and advisors. On June 26, 2017 and on December 28, 2017, the Company’s Board of Directors approved the reservation of 463,384 and 559,764 additional ordinary shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary Shares). On February 25, 2021 and November 17, 2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan, as amended, also contains an “evergreen” provision, which provides for an automatic allotment of ordinary shares to be added every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of the following: (i) 4% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined in advance of January 1 by the board of directors. As of December 31, 2021, our 2017 Plan, as amended, has up to 1,520,066 ordinary shares available for issuance. The Company estimates the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon the Company’s historical share price and historical volatilities of similar entities in the related sector index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The following table lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options for the above Options Plans for the years 2021 and 2020: Year ended 2021 2020 Dividend yield 0% 0% Expected volatility of the share prices 65% 74%-79% Risk-free interest rate 1.4%-1.5% 0.6%-1.38 Expected term (in years) 8 8 Based on the above inputs, the fair value of the options was determined to be $1.52 - $5.64 per option at the grant date. b. The following table summarizes the number of options granted to employees under the Option Plans for the years ended December 31, 2021 and related information: Amount of options Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate intrinsic value Balance as of December 31, 2020 3,892,714 $ 5.15 6.65 $ 608,179 Granted 1,318,351 7.33 - - Exercised (438,759 ) 1.43 - - Forfeited (217,325 ) 7.20 - - Expired (143,557 ) 7.08 - - Balance as of December 31, 2021 4,411,424 6.01 8.19 92,507 Exercisable as of December 31, 2021 2,171,616 $ 5.57 7.11 $ 92,507 As of December 31, 2021, there are $9,739 of total unrecognized costs related to share-based compensation that is expected to be recognized over a period of up to four years. c. The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of December 31, 2021: Exercise price Options outstanding as of December 31, Weighted average remaining contractual term (years) Options exercisable as of December 31, 2021 Weighted average remaining contractual term $ 0.25-3.80 435,346 9.18 123,494 5.82 $ 4.15- 4.95 2,331,999 7.67 1,578,326 7.09 $ 5.21-7.56 546,150 8.62 210,074 7.41 $ 8.00-11.01 1,097,929 8.70 259,722 7.58 4,411,424 2,171,616 d. A summary of restricted shares activity for the year ended December 31, 2021 is as follows: Amount of restricted shares Weighted average grant date fair value Unvested as of December 31, 2020 - $ - Granted 549,427 5.61 Vested - Forfeited (17,950 ) 9.51 Unvested as of December 31, 2021 531,477 $ 5.48 e. The total share-based compensation expense related to all of the Company's equity-based awards, recognized for the years ended December 31, 2021 and 2020 is comprised as follows: Year ended 2021 2020 (in thousands) Research and development expenses, net $ 1,384 $ 1,099 Commercial expenses 947 376 General and administrative expenses 1,902 1,893 Total share-based compensation $ 4,233 $ 3,368

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 12: TAXES ON INCOME a. Tax rates applicable to the income of the Company: 1. Corporate tax rates Taxable income of the Israeli parent is subject to the Israeli corporate tax at the rate of 23% in 2021 and 2020. The Subsidiary is taxed according to the tax laws in its country of residence. 2. Income tax benefits Income is subject to tax benefits under the Law for Encouragement of Capital Investments, 1959 (the “Investment Law”), which provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent decades. The Israeli parliament enacted a reform to the Investment Law, effective January 2011. According to the reform, a flat rate tax applies to companies eligible for the “Preferred Enterprise” status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country’s economic growth and is a competitive factor for the gross domestic product. The Company’s Israeli operations elected “Preferred Enterprise” status, starting in 2017. Benefits granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate for Area A will be 7.5% in 2017 onwards. In other regions, the tax rate is 16%. Preferred Enterprises in peripheral regions will be eligible for Investment Center grants, as well as the applicable reduced tax rates. b. The Law for the Encouragement of Industry (Taxation), 1969: The Company has the status of an “industrial company”, under this law. According to this status and by virtue of regulations published thereunder, the Company is entitled to claim a deduction of accelerated depreciation on equipment used in industrial activities, as determined in the regulations issued under the law. The Company is also entitled to amortize a patent or knowhow usage right that is used in the enterprise’s development or promotion, to deduct listed share issuance expenses and to file consolidated financial statements under certain conditions. c. The components of the loss were as follows: Year ended 2021 2020 Domestic $ 55,853 $ 45,871 Foreign 33,940 15,702 $ 89,793 $ 61,573 d. Net operating losses carryforward: The Company has net operating losses and capital losses for tax purposes as of December 31, 2021 totaling approximately $236,875 and $507, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2021, the Subsidiary has net operating losses carryforwards of $33,100 for federal tax purposes. e. Final tax assessments: The Company’s tax assessments through the 2016 tax year are considered final. f. Deferred taxes: The Company provided a full valuation allowance, to reduce deferred tax assets to their estimated realizable value, since it is more likely than not that all of the deferred tax assets will not be realized.

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE	NOTE 13: BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period, in accordance with ASC No. 260-10 “Earnings Per Share”. The Company experienced a loss in the year ended December 31, 2021; hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect. Details of the number of shares and loss used in the computation of net loss per share: Year ended December 31, 2021 2020 Weighted number of shares Net loss attributable to equity holders of the Company Weighted number of shares Net loss attributable to equity holders of the Company For the computation of basic and diluted loss 59,246,803 $ 89,793 43,725,584 $ 61,573

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation of the financial statements	a. Basis of presentation of the financial statements: The Company’s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) as set forth in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (ASC). Prior to 2021, the Company prepared its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB), as permitted in the United States based on the Company’s qualification as a “foreign private issuer” under the rules and regulations of the U.S Securities and Exchange Commission (the “SEC”). In connection with the loss of the Company’s status as a foreign private issuer effective on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP.
Use of estimates	b. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.
Principles of consolidation	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.
Consolidated financial statements in U.S dollars	d. Consolidated financial statements in U.S dollars: The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiary operates and conducts their transactions. Most of the Company’s costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC No. 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the statements of operations as financing income or expenses as appropriate.
Cash and cash equivalents	e. Cash and cash equivalents: Cash equivalents are short-term highly liquid deposits that are readily convertible to cash with original maturities of three months or less, at the date acquired.
Investments in marketable securities	f. Investments in marketable securities: The Company’s investment in marketable securities consist primarily of trading bonds with a quoted market price that are classified as trading securities pursuant to ASC 320 “Investments — Debt Securities.” Marketable securities are stated at fair value as determined by the closing price of each security at balance sheet date. Unrealized gains and losses on these securities are included in financing income in the consolidated statements of operations.
Restricted short-term and long-term deposits	g. Restricted short-term and long-term deposits: Restricted short-term deposits are deposits with maturities of up to one year and are used as security for the Company’s credit cards. Restricted short-term deposits amounted to $500 and $152 as of December 31, 2021 and 2020, respectively, and are included in prepaid expenses and other current assets in the consolidated balance sheets.
Property, plant and equipment	h. Property, plant and equipment: Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants, excluding day-to-day servicing expenses. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Machinery 10 - 15 Office, furniture and equipment 6 - 33 Leasehold improvements (*) Project in process- manufacturing plant (**) (*) Over the shorter of the term of the lease or its useful life. (**) As of December 31, 2021, the manufacturing plant is under validation process and therefore is not yet ready for production. Depreciation of the manufacturing plant will commence upon completion of the validation process.
Impairment of long-lived assets	i. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets through an impairment charge, to their estimated fair values. During the years ended December 31, 2021 and 2020, no impairment indicators have been identified.
Research and development expenses	j. Research and development expenses: Research and development expenses net of grants are recognized in the consolidated statements of operations when incurred. Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, and executing pre-clinical and clinical studies. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as incurred. Royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by the IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognized the amounts of grants received in research and development as a reduction from research and development expenses in the amount of $2,189 and $1,204 for the years ended December 31, 2021 and 2020, respectively.
Convertible senior notes	k. Convertible senior notes: The Company accounts for its convertible senior notes in accordance with ASC 470-20 “Debt with Conversion and Other Options”. The Company early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40. The Company’s convertible senior notes are included in the calculation of diluted earnings per share (the “EPS”) if the assumed conversion into ordinary shares is dilutive, using the “if-converted” method. This involves adding back the periodic non-cash interest expense net of taxes associated with the convertible senior notes to the numerator and by adding the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the denominator for the purposes of calculating diluted EPS. Since the effect of the convertible senior notes on the diluted EPS was antidilutive, the Company did not include them in the calculation of the diluted EPS.
Share-based compensation	l. Share-based compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation - Stock Compensation”, which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line basis when the only condition to vesting is continued service. The Company has selected the binominal option-pricing model as the most appropriate fair value method for its option awards. The fair value of restricted shares is based on the closing market value of the underlying shares at the date of grant. The Company recognizes forfeitures of equity-based awards as they occur.
Employee benefit liabilities	m. Employee benefit liabilities: The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits are benefits that are expected to be settled entirely before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. 2. Severance pay The majority of the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (the “ Severance Pay Law Severance Pay Law For the Company’s employees in Israel who are not subject to Section 14 of the Severance Pay Law, the Company has a liability for severance pay pursuant to the Severance Pay Law based on the most recent salary of these employees multiplied by the number of years of employment as of the balance sheet date. The Company’s liability for these employees is fully provided for by monthly deposits with severance pay funds, insurance policies and accruals. The deposited funds include profits accumulated up to the balance sheet date. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Severance Pay Law or labor agreements. The severance pay fund amounted to $2,148 and $2,191 as of December 31, 2021 and 2020, respectively. Accrued severance pay is $2,396 and $2,426 as of December 31, 2021 and 2020, respectively.
Fair value of financial instruments	n. Fair value of financial instruments: The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data are available. The carrying amounts of cash and cash equivalents, marketable securities, other receivables, short-term deposits, prepaid expenses and other current assets, trade payables, accrued expenses and other payables approximate their fair value due to the short-term maturity of such instruments.
Leases	o. Leases: The Company accounts for leases according to ASC 842, “Leases”. The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize right-of-use (“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. An ROU asset represents the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease agreement. An ROU asset is measured based on the discounted present value of the remaining lease payments, plus any initial direct costs incurred and prepaid lease payments, excluding lease incentives. The lease liability is measured at lease commencement date based on the discounted present value of the remaining lease payments. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (“IBR”) based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. Payments under the Company’s lease arrangements are primarily fixed however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease right-of-use assets and liabilities. Variable lease payments are primarily comprised of payments affected by common area maintenance and utility charges.
Income taxes	p. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”, which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. ASC 740 offers a two-step approach for recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.
Basic and diluted net loss per share	q. Basic and diluted net loss per share: The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis. These participating securities do not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities. The Company’s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive ordinary shares are anti-dilutive.
Recently issued accounting standards	r. Recently issued accounting standards: In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Effective January 1, 2021, the Company early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of useful life of the assets at annual rate	% Machinery 10 - 15 Office, furniture and equipment 6 - 33 Leasehold improvements (*) Project in process- manufacturing plant (**)

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of the fair value of trading marketable securities	As of Fair value Corporate debentures $ 19,605 Government debentures 20,429 Total $ 40,034

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Year ended 2021 2020 Cost: Machinery $ 4,345 $ 3,545 Leasehold improvements 1,447 1,542 Office, furniture and equipment 800 627 Production plant in process 32,644 16,149 39,236 21,863 Less - accumulated depreciation (4,056 ) (3,625 ) Depreciated cost $ 35,180 $ 18,238

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of operating lease costs	Year ended December 31, 2021 2020 Operating lease costs $ 2,391 $ 2,140 Short-term lease costs 103 43 Total lease costs $ 2,494 $ 2,183
Schedule of operating leases	Year ended December 31, 2021 2020 Weighted average remaining lease term (in years) 4.31 5.17 Weighted average discount rate 2.54 % 2.45 %
Schedule of maturities of lease liabilities	As of 2022 $ 2,771 2023 1,801 2024 1,808 2025 1,316 2026 790 Thereafter 613 Total undiscounted lease payments 9,099 Less: Imputed interest (797 ) Present value of lease liabilities $ 8,302

Convertible Senior Notes, Net (

Convertible Senior Notes, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]
Schedule of liability and equity components of the convertible notes	As of 2021 Liability component: Principal amount $ 75,000 Issuance costs (4,223 ) Net issuance costs $ 70,777 Amortized issuance costs 640 Net carrying amount $ 71,417

Accrued Expenses and Other Pa_2

Accrued Expenses and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of accrued expenses and other payables	Year ended 2021 2020 Subcontractors $ 517 $ 609 Clinical activities 5,445 4,841 Professional services 740 1,943 Production plant in process 983 415 Other 180 180 $ 7,865 $ 7,988

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of fair value of money market funds and marketable securities	December 31, 2021 2020 Level 1 Level 2 Total Level 1 Level 2 Total Cash equivalents: Money market funds $ 51,021 $ - $ 51,021 $ 123 $ - $ 123 Marketable securities: Corporate debentures - 19,605 19,605 - - - Government debentures - 20,429 20,429 - - - Total assets measured at fair value $ 51,021 $ 40,034 $ 91,055 $ 123 $ - $ 123

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of fair value measurement of equity-settled share options	Year ended 2021 2020 Dividend yield 0% 0% Expected volatility of the share prices 65% 74%-79% Risk-free interest rate 1.4%-1.5% 0.6%-1.38 Expected term (in years) 8 8
Schedule of stock option plans	Amount of options Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate intrinsic value Balance as of December 31, 2020 3,892,714 $ 5.15 6.65 $ 608,179 Granted 1,318,351 7.33 - - Exercised (438,759 ) 1.43 - - Forfeited (217,325 ) 7.20 - - Expired (143,557 ) 7.08 - - Balance as of December 31, 2021 4,411,424 6.01 8.19 92,507 Exercisable as of December 31, 2021 2,171,616 $ 5.57 7.11 $ 92,507
Schedule of outstanding and exercisable option granted	Exercise price Options outstanding as of December 31, Weighted average remaining contractual term (years) Options exercisable as of December 31, 2021 Weighted average remaining contractual term $ 0.25-3.80 435,346 9.18 123,494 5.82 $ 4.15- 4.95 2,331,999 7.67 1,578,326 7.09 $ 5.21-7.56 546,150 8.62 210,074 7.41 $ 8.00-11.01 1,097,929 8.70 259,722 7.58 4,411,424 2,171,616
Schedule of of restricted shares activity	Amount of restricted shares Weighted average grant date fair value Unvested as of December 31, 2020 - $ - Granted 549,427 5.61 Vested - Forfeited (17,950 ) 9.51 Unvested as of December 31, 2021 531,477 $ 5.48
Schedule of share-based compensation expense	Year ended 2021 2020 (in thousands) Research and development expenses, net $ 1,384 $ 1,099 Commercial expenses 947 376 General and administrative expenses 1,902 1,893 Total share-based compensation $ 4,233 $ 3,368

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule components of the loss	Year ended 2021 2020 Domestic $ 55,853 $ 45,871 Foreign 33,940 15,702 $ 89,793 $ 61,573

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of number of shares and loss used in the computation of net loss per share	Year ended December 31, 2021 2020 Weighted number of shares Net loss attributable to equity holders of the Company Weighted number of shares Net loss attributable to equity holders of the Company For the computation of basic and diluted loss 59,246,803 $ 89,793 43,725,584 $ 61,573

General (Details)

General (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Accounting Policies [Abstract]
Clinical trial on outcomes	The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at two years of 78% (95% CI, 51%–91%) and a safety profile similar to that reported previously.
Accumulated deficit	$ 337,457
Cash	$ 81,760
Operating segment	1

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Short-term investments	$ 500,000	$ 152,000
Restricted long-term amount	3,961,000
Research and development expenses	$ 2,189	1,204
Severance pay percentage	8.33%
Severance costs	$ 2,148	2,191
Accrued severance pay	2,396	2,426
Severance expense	$ 427	$ 12
Tax benefit	50.00%

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate	12 Months Ended
	Dec. 31, 2021
Leasehold improvements[Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate		[1]
Project in process- manufacturing plant [Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate		[2]
Minimum [Member] | Machinery [Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate	10.00%
Minimum [Member] | Office, furniture and equipment [Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate	6.00%
Maximum [Member] | Machinery [Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate	15.00%
Maximum [Member] | Office, furniture and equipment [Member]
Significant Accounting Policies (Details) - Schedule of useful life of the assets at annual rate [Line Items]
Annual depreciation rate	33.00%
[1]	Over the shorter of the term of the lease or its useful life.
[2]	As of December 31, 2021, the manufacturing plant is under validation process and therefore is not yet ready for production. Depreciation of the manufacturing plant will commence upon completion of the validation process.

Marketable Securities (Details)

Marketable Securities (Details) - Schedule of the fair value of trading marketable securities - Marketable Securities [Member] $ in Thousands	Dec. 31, 2021USD ($)
Marketable Securities [Line Items]
Corporate debentures	$ 19,605
Government debentures	20,429
Total	$ 40,034

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 431	$ 357

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cost:
Less - accumulated depreciation	$ (4,056)	$ (3,625)
Depreciated cost	35,180	18,238
Machinery [Member]
Cost:
Machinery	4,345	3,545
Leasehold Improvements [Member]
Cost:
Leasehold improvements	1,447	1,542
Office, Furniture and Equipment [Member]
Cost:
Office, furniture and equipment	800	627
Production Plant in Process [Member]
Cost:
Production plant in process	32,644	16,149
Property, Plant and Equipment, Other Types [Member]
Cost:
property, plant and equipment	$ 39,236	$ 21,863

Leases (Details)

Leases (Details)	Dec. 31, 2021
Leases [Abstract]
Lease term	6 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of operating lease costs [Abstract]
Operating lease costs	$ 2,391	$ 2,140
Short-term lease costs	103	43
Total lease costs	$ 2,494	$ 2,183

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating leases	Dec. 31, 2021	Dec. 31, 2020
Schedule of operating leases [Abstract]
Weighted average remaining lease term (in years)	4 years 3 months 21 days	5 years 2 months 1 day
Weighted average discount rate	2.54%	2.45%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of maturities of lease liabilities $ in Thousands	Dec. 31, 2021USD ($)
Schedule of maturities of lease liabilities [Abstract]
2022	$ 2,771
2023	1,801
2024	1,808
2025	1,316
2026	790
Thereafter	613
Total undiscounted lease payments	9,099
Less: Imputed interest	(797)
Present value of lease liabilities	$ 8,302

Convertible Senior Notes, Net_2

Convertible Senior Notes, Net (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Convertible Senior Notes, Net (Details) [Line Items]
Principal amount	$ 75,000,000
Annual Interest Percentage	5.875%
Convertible notes payable	$ 1,000,000
Ordinary shares (in Shares) | shares	56.3063
Principal amount	$ 1,000,000
Exchange price (in Dollars per share) | $ / shares	$ 17.76
Repurchase price	100.00%
Exchange price Percentage	130.00%
Convertible notes	$ 4,223
Effective interest rate	7.37%
Convertible Notes [Member]
Convertible Senior Notes, Net (Details) [Line Items]
Principal amount	$ 1,000,000
Repurchase price	100.00%

Convertible Senior Notes, Net_3

Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Schedule of liability and equity components of the convertible notes [Abstract]
Principal amount	$ 75,000
Issuance costs	(4,223)
Net issuance costs	70,777
Amortized issuance costs	640
Net carrying amount	$ 71,417

Accrued Expenses and Other Pa_3

Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses and other payables [Abstract]
Subcontractors	$ 517	$ 609
Clinical activities	5,445	4,841
Professional services	740	1,943
Production plant in process	983	415
Other	180	180
Total	$ 7,865	$ 7,988

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash equivalents:
Money market funds	$ 51,021	$ 123
Marketable securities:
Corporate debentures	19,605
Government debentures	20,429
Total assets measured at fair value	91,055	123
Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Money market funds	51,021	123
Marketable securities:
Corporate debentures
Government debentures
Total assets measured at fair value	51,021	123
Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Money market funds
Marketable securities:
Corporate debentures	19,605
Government debentures	20,429
Total assets measured at fair value	$ 40,034

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Contingent Liabilities and Commitments (Details) [Line Items]
Bank guarantees amount	$ 3,334
Investment Center grant amount	3,171
Aggregate amount	37,300
Royalty-bearing grants	34,700
Non-royalty-bearing grants	$ 2,600
Percentage of interest rate	100.00%
Total grants	$ 44,700
Maximum [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Royalties rate	3.50%
Minimum [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Royalties rate	3.00%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - shares	1 Months Ended		12 Months Ended
	Dec. 31, 2020	May 31, 2020	Dec. 31, 2021
Shareholders' Equity (Details) [Line Items]
Underwriters description	In December 2020, the Company closed a third follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of 9,343,750 ordinary shares at a public offering price of $8.00 per share, before underwriting discounts and inclusive of the underwriters’ exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $68,988 from the offering (net of issuance costs and underwriting discounts of $5,762).	In May 2020, the Company closed a second follow-on offering of its ordinary shares on Nasdaq, which resulted in the sale of a total of 15,333,334 ordinary shares at a public offering price of $4.50 per share, before underwriting discounts and inclusive of the underwriters’ exercise in full of their option to purchase additional shares in the offering. The Company received proceeds in the amount of $63,860 from the offering (net of issuance costs and underwriting discounts of $5,140).
Expire date			As part of its 2017 investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022.
2017 Investor Member
Shareholders' Equity (Details) [Line Items]
Granted Warrants			4,323,978
Warrant [Member]
Shareholders' Equity (Details) [Line Items]
Granted Warrants			1,010,466

Share-Based Compensation (Detai

Share-Based Compensation (Details) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 23, 2014₪ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 28, 2017shares	Jun. 26, 2017shares	Jan. 23, 2017₪ / sharesshares
Share-Based Compensation (Details) [Line Items]
Options vest period	3 years	4 years
Ordinary shares outstanding percentage		4.00%
Ordinary shares issuance		1,520,066
Share-based compensation non-vested (in Dollars) | $		$ 9,739
Minimum [Member]
Share-Based Compensation (Details) [Line Items]
Grant date fair value per share (in Dollars per share) | $ / shares		$ 1.52
Maximum [Member]
Share-Based Compensation (Details) [Line Items]
Grant date fair value per share (in Dollars per share) | $ / shares		$ 5.64
2017 Share Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Nominal per share value (in New Shekels per share) | ₪ / shares					₪ 0.01
Number of shares reserved for issuance		1,338,015	559,764	463,384	312,867
Ordinary C Share [Member]
Share-Based Compensation (Details) [Line Items]
Nominal per share value (in New Shekels per share) | ₪ / shares	₪ 0.01
Ordinary shares	1,500,000
Ordinary C Share [Member] | 2014 Israel Share Option Plan [Member]
Share-Based Compensation (Details) [Line Items]
Ordinary shares issued	1,152,044

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility of the share prices	65.00%
Expected term (in years)	8 years	8 years
Minimum [Member]
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Expected volatility of the share prices		74.00%
Risk-free interest rate	1.40%	0.60%
Maximum [Member]
Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options [Line Items]
Expected volatility of the share prices		79.00%
Risk-free interest rate	1.50%	1.38%

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Schedule of stock option plans [Abstract]
Amount of options, beginning Balance | shares	3,892,714
Weighted average exercise price, beginning Balance | $ / shares	$ 5.15
Weighted average remaining contractual term (in years), beginning Balance	6 years 7 months 24 days
Aggregate intrinsic value, beginning Balance | $	$ 608,179
Amount of options, Granted | shares	1,318,351
Weighted average exercise price, Granted | $ / shares	$ 7.33
Weighted average remaining contractual term (in years), Granted
Aggregate intrinsic value, Granted | $
Amount of options, Exercised | shares	(438,759)
Weighted average exercise price, Exercised | $ / shares	$ 1.43
Weighted average remaining contractual term (in years), Exercised
Aggregate intrinsic value, Exercised | $
Amount of options, Forfeited | shares	(217,325)
Weighted average exercise price, Forfeited | $ / shares	$ 7.2
Weighted average remaining contractual term (in years), Forfeited
Aggregate intrinsic value, Forfeited | $
Amount of options, Expired | shares	(143,557)
Weighted average exercise price, Expired | $ / shares	$ 7.08
Weighted average remaining contractual term (in years), Expired
Aggregate intrinsic value, Expired | $
Amount of options, ending Balance | shares	4,411,424
Weighted average exercise price, ending Balance | $ / shares	$ 6.01
Weighted average remaining contractual term (in years), ending Balance	8 years 2 months 8 days
Aggregate intrinsic value, ending Balance | $	$ 92,507
Amount of options, Exercisable | shares	2,171,616
Weighted average exercise price, Exercisable | $ / shares	$ 5.57
Weighted average remaining contractual term (in years), Exercisable	7 years 1 month 9 days
Aggregate intrinsic value, Exercisable | $	$ 92,507

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted	12 Months Ended
	Dec. 31, 2021shares
Options Outstanding [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options outstanding	4,411,424
Options Exercisable [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options exercisable	2,171,616
0.25-3.8 [Member] | Options Outstanding [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options outstanding	435,346
Weighted average remaining contractual term (Years)	9 years 2 months 4 days
0.25-3.8 [Member] | Options Exercisable [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Weighted average remaining contractual term (Years)	5 years 9 months 25 days
Options exercisable	123,494
4.15- 4.95 [Member] | Options Outstanding [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options outstanding	2,331,999
Weighted average remaining contractual term (Years)	7 years 8 months 1 day
4.15- 4.95 [Member] | Options Exercisable [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Weighted average remaining contractual term (Years)	7 years 1 month 2 days
Options exercisable	1,578,326
5.21-7.56 [Member] | Options Outstanding [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options outstanding	546,150
Weighted average remaining contractual term (Years)	8 years 7 months 13 days
5.21-7.56 [Member] | Options Exercisable [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Weighted average remaining contractual term (Years)	7 years 4 months 28 days
Options exercisable	210,074
8.00-11.01 [Member] | Options Outstanding [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Options outstanding	1,097,929
Weighted average remaining contractual term (Years)	8 years 8 months 12 days
8.00-11.01 [Member] | Options Exercisable [Member]
Share-Based Compensation (Details) - Schedule of outstanding and exercisable option granted [Line Items]
Weighted average remaining contractual term (Years)	7 years 6 months 29 days
Options exercisable	259,722

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of of restricted shares activity	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Schedule of of restricted shares activity [Abstract]
Amount of restricted shares, Unvested beginning
Weighted average grant date fair value, Unvested beginning (in Dollars per share) | $ / shares
Amount of restricted shares, Granted	549,427
Weighted average grant date fair value, Granted (in Dollars per share) | $ / shares	$ 5.61
Amount of restricted shares, Vested
Amount of restricted shares, Forfeited	(17,950)
Weighted average grant date fair value, Forfeited (in Dollars per share) | $ / shares	$ 9.51
Amount of restricted shares, Unvested ending	531,477
Weighted average grant date fair value, Unvested ending (in Dollars per share) | $ / shares	$ 5.48

Share-Based Compensation (Det_6

Share-Based Compensation (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of share-based compensation expense [Abstract]
Research and development expenses, net	$ 1,384	$ 1,099
Commercial expenses	947	376
General and administrative expenses	1,902	1,893
Total share-based compensation	$ 4,233	$ 3,368

Taxes on Income (Details)

Taxes on Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Israeli corporate income tax	23.00%	23.00%
Description of corporate tax rate	Benefits granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate for Area A will be 7.5% in 2017 onwards. In other regions, the tax rate is 16%. Preferred Enterprises in peripheral regions will be eligible for Investment Center grants, as well as the applicable reduced tax rates.
Description of net carryforward tax losses	The Company has net operating losses and capital losses for tax purposes as of December 31, 2021 totaling approximately $236,875 and $507, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period.
Net operating losses carryforwards	$ 33,100

Taxes on Income (Details) - Sch

Taxes on Income (Details) - Schedule components of the loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule components of the loss [Abstract]
Domestic	$ 55,853	$ 45,871
Foreign	33,940	15,702
Total net loss (income) before income taxes	$ 89,793	$ 61,573

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share - For the computation of diluted loss [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Line Items]
Weighted number of shares	59,246,803	43,725,584
Net loss attributable to equity holders of the Company	$ 89,793	$ 61,573